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Superficial venous thrombosis (SVT) prognosis is debated and its management is
highly variable. It was the objective of this study to assess predictive risk factors for
concurrent deep-vein thrombosis (DVT) at presentation and for three-month adverse
outcome. Using data from the prospective multicentre OPTIMEV study, we analysed
SVT predictive factors associated with concurrent DVT and three-month adverse
outcome. Out of 788 SVT included, 227 (28.8%) exhibited a concurrent DVT at
presentation. Age >75years (odds ratio [OR]=2.9 [1.5-5.9]), active cancer (OR=2.6
[1.3-5.2]), inpatient status (OR=2.3 [1.2-4.4]) and SVT on non-varicose veins
(OR=1.8 [1.1-2.7]) were significantly and independently associated with an increased
risk of concurrent DVT. 39.4% of SVT on non-varicose veins presented a concurrent
DVT. However, varicose vein status did not influence the three-month prognosis as
rates of death, symptomatic venous thromboembolic (VTE) recurrence and major
bleeding were equivalent in both non-varicose and varicose SVTs (1.4% vs. 1.1%;
3.4% vs. 2.8%; 0.7% vs. 0.3%). Only male gender (OR=3.5 [1.1-11.3]) and inpatient
status (OR=4.5 [1.3-15.3]) were independent predictive factors for symptomatic VTE
recurrence but the number of events was low (n=15, 3.0%). Three-month numbers of
deaths (n=6, 1.2%) and of major bleedings (n=2, 0.4%) were even lower, precluding
any relevant interpretation. In conclusion, SVT on non-varicose veins and some
classical risk factors for DVT were predictive factors for concurrent DVT at
presentation. As SVT remains mostly a clinical diagnosis, these data may help
selecting patients deserving an ultrasound examination or needing anticoagulation
while waiting for diagnostic tests. Larger studies are needed to evaluate predictive
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